Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
세계의 진행성 운동실조증 및 근력 저하증 치료제 시장 규모는 2022년 320억 달러, 2023년 351억 달러에서 예측 기간 중 10.2%의 CAGR로 추이하며, 2028년에는 572억 달러 규모로 성장할 것으로 예측됩니다.
진행성근력 저하증 부문은 2022년 299억 달러, 2023년 328억 달러에서 10.0%의 CAGR로 추이하며, 2028년에는 528억 달러에 달할 것으로 예측되고 있습니다. 또한 진행성 운동실조증 부문은 2022년 21억 달러, 2023년 24억 달러에서 13.3%의 CAGR로 추이하며, 2028년에는 44억 달러 규모로 성장할 것으로 예측됩니다.
세계의 진행성 운동실조증 및 근력 저하증 치료제 시장을 조사했으며, 질환의 개요·분류, 시장 영향요인 및 시장 기회 분석, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 기술 및 특허의 동향, ESG 개발, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 요약·하이라이트
제3장 시장 개요
- 정의
- 분류
- 진행성 운동실조증 및 근력 저하증
- 진행성 운동실조증 및 근력 저하증 진단 검사
제4장 시장 역학
- 시장 촉진요인
- 시장 장벽
- 시장 기회
- COVID-19의 시장에 대한 영향
제5장 시장 내역 : 유형·기술별
- 유형별
- 시장 개요
- 시장 매출
- 기술별
- 시장 개요
- 시장 매출
- 저분자
- 시장 개요
- 시장 매출
- 모노클로널 항체
- 시장 개요
- 시장 매출
- 기타
- 바이오마커
- 유전자 치료
- 줄기세포
- 시장 개요
- 시장 매출
제6장 시장 내역 : 질환별
- 개요
- 시장 매출
- 진행성 운동실조증의 유형별 시장
- Friedreich's Ataxia
- 시장 매출
- Machado-Joseph disease(MJD)/SCA3
- 시장 매출
- Gertsmann-Straussler-Scheinker Disease
- 시장 매출
- 질환 유형별 시장
- 근위축성 측색 경화증
- 진행성구 마비
- Hereditary Spastic Paraplegia
- 유전성 신경장애(HN)
- 다발성 경화증(MS)
제7장 시장 내역 : 지역별
- 북미
- 미국
- 캐나다
- 유럽
- 영국
- 독일
- 프랑스
- 스페인
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 기타 아시아태평양
- 세계의 기타 지역
- 시장 규모·예측
제8장 시장 내역 : 유통 채널별
제9장 새로운 기술과 개발
- 신규 기술
- 줄기세포 요법
- 유전자 치료
- 바이오마커
- MS용 점비약
- 질환 조절 요법
- RNA 기반 요법
- 결론
제10장 ESG 개발
- 주요 기업에 의한 ESG 투자
- ESG에 대한 소비자 의식
- 결론
제11장 특허 분석
제12장 M&A 및 벤처 자금조달 전망·경쟁 구도
- M&A·제휴
- 전략적 구상
- 제조업체의 시장 점유율
제13장 기업 개요
- ABBOTT LABORATORIES
- ACORDA THERAPEUTICS INC.
- AMERICAN REGENT INC.
- APOTEX INC.
- APOTHECA INC.
- ASTELLAS PHARMA INC.
- ASTRAZENECA GMBH
- BAXTER INTERNATIONAL INC.
- BRISTOL-MYERS SQUIBB
- EISAI CO. LTD.
- ELI LILLY AND COMPANY
- GILEAD SCIENCES INC.
- GLAXOSMITHKLINE PLC
- GLENMARK LIFE SCIENCES
- JOHNSON & JOHNSON
- MERCK KGAA
- NOVARTIS AG
- PFIZER INC.
- ROCHE HOLDING LTD.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
제14장 부록 : 약어
KSA
Highlights:
The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.
Progressive weakness syndromes segment of the global progressive ataxia and weakness disorders market reached $29.9 billion in 2022, should reach $32.8 billion by 2023 and $52.8 billion by 2028 with a CAGR of 10.0% during the forecast period of 2023-2028.
Progressive ataxia segment of the global progressive ataxia and weakness disorders market reached $2.1 billion in 2022, should reach $2.4 billion by 2023 and $4.4 billion by 2028 with a CAGR of 13.3% during the forecast period of 2023-2028.
Report Scope:
The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.
This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.
Report Includes:
- 34 data tables and 34 additional tables
- A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
- Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
- In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market
- Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region
- Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
- Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth
- Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments
- Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders
- Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration
- Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi
Table of Contents
Chapter 1 Introduction
- Overview
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- What's New in This Update?
- Methodology
- Information Sources
- Geographic Breakdown
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
- Introduction
- Definitions
- Neurons
- Central Nervous System
- Brain
- Spinal Cord
- Neurotransmitters
- Classification
- Progressive Ataxia and Weakness Disorders
- Friedreich's Ataxia
- Gertsmann-Straussler-Scheinker Disease
- Machado-Joseph Disease/SCA3
- Amyotrophic Lateral Sclerosis
- Hereditary Spastic Paraplegia
- Hereditary Neuropathies
- Multiple Sclerosis
- Diagnostic Tests for Progressive Ataxia and Weakness Disorders
- Diagnostic Tests for Multiple Sclerosis
- Diagnostic Tests for Amyotrophic Lateral Sclerosis
- Diagnostic Tests for Friedreich's Ataxia
- Diagnostic Tests for Machado-Joseph Disease
- Diagnostic Tests for Hereditary Spastic Paraplegia
- Diagnostic Tests for Hereditary Neuropathies
Chapter 4 Market Dynamics
- Introduction
- Market Drivers
- Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
- Technological Advancements and Product Launch
- Increasing Expenditures for Health Care
- Rise in Alcohol and Drug Use
- Market Barriers
- Barriers to R&D for Progressive Ataxia
- Diagnostic Challenges
- Opportunities
- Advancements in Research and Technology
- Impact of COVID-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders
Chapter 5 Market Breakdown by Type and Technology
- Introduction
- Market by Type
- Market Overview
- Market Revenue
- Market by Technology
- Market Overview
- Market Revenue
- Small Molecule
- Market Overview
- Market Revenue
- Monoclonal Antibody
- Market Overview
- Market Revenue
- Others
- Biomarkers
- Gene Therapy
- Stem Cell
- Market Overview
- Market Revenue
Chapter 6 Market Breakdown by Disease
- Overview
- Market Revenue
- Market by Progressive Ataxia Diseases Type
- Friedreich's Ataxia
- Market Revenue
- Machado-Joseph disease (MJD)/SCA3
- Market Revenue
- Gertsmann-Straussler-Scheinker Disease
- Market Revenue
- Market by Disease Type
- Amyotrophic Lateral Sclerosis
- Progressive Bulbar Palsy
- Hereditary Spastic Paraplegia
- Hereditary Neuropathies (HNs)
- Multiple Sclerosis (MS)
Chapter 7 Market Breakdown by Region
- Introduction
- North America
- The U.S.
- Canada
- Europe
- The UK
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Market Size and Forecast
Chapter 8 Market Breakdown by Distribution Channel
- Introduction
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Chapter 9 Emerging Technologies and Developments
- Introduction
- Emerging Technology
- Stem Cell Therapy
- Gene Therapy
- Biomarkers
- Nasal Spray for MS
- Disease-modifying Therapies
- RNA-based Therapies
- Conclusion
Chapter 10 ESG Development
- Introduction
- ESG Investments by Key Players
- Consumer Attitudes Towards ESG
- Conclusion
Chapter 11 Patent Analysis
Chapter 12 M&A and Venture Funding Outlook and Competitive Landscape
- Introduction
- Mergers, Acquisitions and Collaborations
- Strategic Initiatives
- Market Shares of Manufacturers of Progressive Ataxia and Weakness Disorders Drugs
Chapter 13 Company Profiles
- ABBOTT LABORATORIES
- ACORDA THERAPEUTICS INC.
- AMERICAN REGENT INC.
- APOTEX INC.
- APOTHECA INC.
- ASTELLAS PHARMA INC.
- ASTRAZENECA GMBH
- BAXTER INTERNATIONAL INC.
- BRISTOL-MYERS SQUIBB
- EISAI CO. LTD.
- ELI LILLY AND COMPANY
- GILEAD SCIENCES INC.
- GLAXOSMITHKLINE PLC
- GLENMARK LIFE SCIENCES
- JOHNSON & JOHNSON
- MERCK KGAA
- NOVARTIS AG
- PFIZER INC.
- ROCHE HOLDING LTD.
- SANOFI
- TAKEDA PHARMACEUTICAL CO. LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 14 Appendix: Abbreviations
